Company Profile

HLB Science Inc, formerly DanDi Bioscience Inc, is a Korea-based company principally engaged in the research and development of biological pharmaceuticals. The Company is engaged in the research and development of sepsis treatment, antibiotics for super bacteria, dementia treatment, dementia diagnostic kits and other medicines products.

Employees

Sector

Biotechnology & Medical Research

More about the company

12-31	HLB Co., Ltd. completed the acquisition of HLB SCIENCE Inc. from HLB GLOBAL Co., Ltd., HLB bioStep Co.,Ltd., HLB Life Science Co., Ltd., Yoon Jong-seon and others.	CI
10/10/24	HLB SCIENCE Inc. announced that it has received KRW 2.999998812 billion in funding from HLB Life Science Co., Ltd.	CI
24/09/24	HLB SCIENCE Inc. announced that it expects to receive KRW 2.999998812 billion in funding from HLB Life Science Co., Ltd.	CI
26/09/23	HLB SCIENCE Inc. announced that it has received KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	CI
18/09/23	HLB SCIENCE Inc. announced that it expects to receive KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	CI
09/02/23	HLB SCIENCE Inc. announced that it has received KRW 5.0000004 billion in funding from HLB bioStep Co.,Ltd.	CI
01/02/23	HLB SCIENCE Inc. announced that it expects to receive KRW 5.0000004 billion in funding from HLB bioStep Co.,Ltd.	CI
07/07/21	DandiBioscience, Inc. announced that it has received KRW 8.4 billion in funding	CI
15/06/21	DandiBioscience, Inc. announced that it expects to receive KRW 8.4 billion in funding	CI
22/04/21	DandiBioscience, Inc. announced that it has received KRW 1.3 billion in funding	CI
16/04/21	DandiBioscience, Inc. announced that it expects to receive KRW 1.3 billion in funding	CI
05/10/19	NEXT SCIENCE Co.,Ltd. cancelled the acquisition of 45.4% stake in Dandi Bioscience Inc.	CI
28/03/19	Dandi Bio Science Co.,Ltd. announced that it has received KRW 4.164081 billion in funding from Next Science Co., Ltd.	CI

Manager	Title	Age	Since
Jong-Sun Yoon CEO	Chief Executive Officer	61	23/03/2022
Jong-Chan Song AUD	Comptroller/Controller/Auditor	60	25/03/2021

Director	Title	Age	Since
Jong-Sun Yoon BRD	Director/Board Member	61	23/03/2022
Yang-Gon Jin BRD	Director/Board Member	60	-
Ki-Hwan Kim BRD	Director/Board Member	56	26/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HLB SCIENCE INC.	+0.97%	+1.71%	-	-	26.49M
WUXI APPTEC CO., LTD.	+0.01%	+11.10%	+60.83%	+70.43%	68.32B
ARGENX SE	+0.69%	+6.77%	+14.11%	+89.13%	60.26B
LONZA GROUP AG	-0.06%	0.00%	+19.68%	+97.14%	55.86B
BEONE MEDICINES AG	+1.60%	+19.44%	+28.80%	+112.95%	48.43B
IQVIA HOLDINGS INC.	-1.32%	+4.78%	+29.15%	+40.40%	45.34B
REVOLUTION MEDICINES, INC.	-3.54%	-0.60%	+207.76%	+879.50%	41.76B
CELLTRION, INC.	-3.33%	+6.90%	+22.78%	+48.07%	34.5B
GENMAB A/S	-1.28%	-1.23%	+84.16%	+56.51%	33.8B
WUXI BIOLOGICS (CAYMAN) INC.	-1.49%	+1.16%	+47.05%	+0.16%	25.96B
Average	-0.77%	+5.39%	+57.15%	+154.92%	46B
Weighted average by Cap.	-0.69%	+5.25%	+53.95%	+152.59%

HLB SCIENCE Inc. Stock

Stocks

A343090

KR7343090007

Biotechnology & Medical Research

Chart: HLB SCIENCE Inc.

Latest news: HLB SCIENCE Inc.

Quotes and Performance

Managers and Directors: HLB SCIENCE Inc.

Bio Therapeutic Drugs

Company Profile